Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Sun Pharma’s acquisition of Innovcare looks like a portfolio-building move in India: for about ₹271.2 crore, Sun is buying a growing busin...
